Now available BRIUMVI™

BRIUMVI™ (ublituximab-xiiy) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.